Commonwealth Sec'y of Virginia v. Miserandino, 522 U.S. 963 (1997). · Go Syfert
Search
Commonwealth Sec'y of Virginia v. Miserandino, 522 U.S. 963 (1997). Cases Citing This Book View Copy Cite
“hen ... a state gives identified victims of state discrimination that were wrongly denied them, the beneficiaries are not granted a preference 'on the basis of race' but on the basis that they have been individually wronged.”
41 citation events (14 in the last 25 years) across 18 distinct courts.
Strongest positive: Green v. Veneman (mssd, 2001-04-02)
Treatment trajectory · 1997 → 2026 · click a year to view as-of
1997 2011 2026
Top citers, strongest first. 6 distinct citers. How cited ↗
examined Cited as authority (quoted) Green v. Veneman
S.D. Miss. · 2001 · quote attribution · 1 verbatim quote · confidence low
hen ... a state gives identified victims of state discrimination that were wrongly denied them, the beneficiaries are not granted a preference 'on the basis of race' but on the basis that they have been individually wronged.
cited Cited "see" Vehicular Technologies Corporation v. Titan Wheel International
Fed. Cir. · 1998 · signal: see · confidence high
See Genentech, Inc. v. Novo Nordisk, A/S, 108 F.3d 1361, 1364 , 42 USPQ2d 1001, 1003 (Fed.Cir.) (Novo Nordisk II ), cert. denied, --- U.S. ----, 118 S.Ct. 397 , 139 L.Ed.2d 310 (1997).
cited Cited "see" Vehicular Technologies Corp. v. Titan Wheel International, Inc.
Fed. Cir. · 1998 · signal: see · confidence high
See Genentech, Inc. v. Novo Nordisk, AJS, 108 F.3d 1361, 1364 , 42 USPQ2d 1001, 1003 (Fed.Cir.) (Novo Nordisk II), cert. denied, - U.S. -, 118 S.Ct. 397 , 139 L.Ed.2d 310 (1997).
discussed Cited "see" Genentech, Inc. v. Boehringer Mannheim GmbH
D. Mass. · 1997 · signal: see · confidence high
See Genentech, Inc. v. Novo Nordisk, 108 F.3d 1361, 1365 (Fed.Cir.1997) (invalidating patent for failure of specification to enable practice of claimed method), cert. denied, —U.S. ---, 118 S.Ct. 397 , 139 L.Ed.2d 310 (1997); Genentech, Inc. v. Wellcome Foundation, Ltd., 29 F.3d 1555, 1564 (Fed.
discussed Cited "see, e.g." Chemical Separation Technology, Inc. v. United States
Fed. Cl. · 2002 · signal: see also · confidence low
See Space Systems/Loral, Inc., 271 F.3d at 1080-81 ; see also Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1365 (Fed.Cir.1997) (“To be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without ‘undue experimentation.’ ”), cert. denied, 522 U.S. 963 , 118 S.Ct. 397 , 139 L.Ed.2d 310 (1997).
discussed Cited "see, e.g." Novo Nordisk A/S v. Becton Dickinson & Co.
S.D.N.Y. · 1998 · signal: see also · confidence low
Validity ofthe-Patents At the preliminary injunction stage, Novo as the patentee, carries the burden of showing likelihood of success on the merits with respect to the patent’s validity, enforceability, and infringement. 23 Nutrition 21, 930 F.2d at 869 ; see also Genentech, Inc. v. Novo Nordisk, A/S, 108 F.3d 1361 , 1364 n. 2 (Fed.Cir.), cert. denied, — U.S. -, 118 S.Ct. 397 , 139 L.Ed.2d 310 (1997); Bio-Technology Gen.
Retrieving the full opinion text from the archive…
Commonwealth Secretary of Virginia
v.
Miserandino et ux.
No. 97-27.
Supreme Court of the United States.
Nov 3, 1997.
522 U.S. 963
Cited by 4 opinions  |  Published
1 passage pin-cited by 1 case
Pinpoint authority: bottom 65%
Citer courts: S.D. Mississippi (1)

Gt. App. Md. Motions of Virginia Creditors Bar Association and Virginia Credit Union League for leave to file briefs as amici curiae granted. Certiorari denied.